Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2021 08:15 ET | Source: Silo Pharma, Inc.

Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities

Englewood Cliffs, NJ, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today...
December 15, 2020 08:30 ET | Source: Silo Pharma, Inc.

Silo Pharma, Inc. Enhances Scientific Advisory Board with Appointment of Dr. Charles B. Nemeroff of University of Texas at Austin

Englewood Cliffs, NJ, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today...
December 07, 2020 08:15 ET | Source: Silo Pharma, Inc.

Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham

NEW JERSEY, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that...
December 04, 2020 16:52 ET | Source: Silo Pharma, Inc.

Silo Pharma Comments on Recent Promotional and Trading Activities at Request of OTC Markets

NEW JERSEY , Dec. 04, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that...
November 16, 2020 09:40 ET | Source: Silo Pharma, Inc.

Silo Pharma, Inc. Expands Scientific Advisory Board with the Appointment of Dr. Joshua Woolley of University of California, San Francisco

NEW YORK , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) today announced that its Board of Directors has named scientific research investigator Dr. Joshua Woolley, M.D. / Ph.D....
November 12, 2020 07:07 ET | Source: Silo Pharma, Inc.

Silo Pharma, Inc. Announces Filing of Three U.S. Provisional Patent Applications

Each Provisional Patent Application Relates to Psilocybin NEW YORK , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on...
November 09, 2020 07:15 ET | Source: Silo Pharma, Inc.

Silo Pharma, Inc. Launches Scientific Advisory Board with Appointment of Dr. Matthew Johnson of John Hopkins University

NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced it has...
October 14, 2020 10:06 ET | Source: Silo Pharma, Inc.

Silo Pharma, Inc. (SILO) Announces Successful Uplisting To the OTCQB Venture Market

To Begin Trading on the OTCQB Venture Market Under the Symbol “SILO” Today NEW YORK , Oct. 14, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage...
October 13, 2020 08:45 ET | Source: Uppercut Brands, Inc.

Silo Pharma, Inc. Enters into Option Agreement with University of Maryland Baltimore for Central Nervous System-Homing Peptides

NEW YORK, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTC Pink: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, announced that it...
October 06, 2020 09:55 ET | Source: Uppercut Brands, Inc.

Silo Pharma, Inc. Expands Board with Appointment of Dr. Kevin Muñoz MD; Announces Application to Uplist to OTCQB Market

NEW YORK , Oct. 06, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTC Pink: SILO), which recently announced its transformation to a developmental stage biopharmaceutical company focused on the use of...